We hereby submit the Annual Report of Asarfi Hospital Limited for the financial year 2024-25, including the Notice convening the Annual General Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asarfi Hospital Limited has submitted its Annual Report for the financial year ended 31 March 2025, along with the notice for its 20th Annual General Meeting scheduled for Friday, 12 September 2025 at 12:00 noon in Dhanbad. The book closure period runs from 6 September to 12 September 2025. For FY25, standalone revenue grew 43% YoY to ₹12,057 lakhs (from ₹8,440 lakhs), EBITDA rose 48% to ₹2,384 lakhs, and PAT surged 161% to ₹1,098 lakhs, lifting PAT margin from 5% to 9% and ROCE to 14%. Patient volumes grew 29% to 1.26 lakh, and the company operated 315 beds across its super-specialty and cancer hospital units in Dhanbad. The AGM will also consider re-appointment of Executive Director Mrs. Madhuri Singh and appointment of Ritu Ritolia & Co. as secretarial auditor for five years.
The strong FY25 numbers, with revenue up 43% and PAT up 161%, should be viewed positively by shareholders, though this filing itself is a routine regulatory disclosure. The AGM agenda items — adoption of accounts, a director re-appointment by rotation, and secretarial auditor appointment — are standard and unlikely to materially affect the stock price on announcement.